Literature DB >> 12397783

Gastrectomy circumstances that influence early postoperative outcome.

Roderich E Schwarz1, Kathryn Zagala-Nevarez.   

Abstract

BACKGROUND/AIMS: Despite decreasing mortality, gastric resection is still a procedure of significant morbidity.
METHODOLOGY: Factors predicting post-gastrectomy outcome over 3 years in a tertiary care cancer center, single-surgeon experience were analyzed.
RESULTS: Thirty-four patients who underwent total or partial gastrectomy at the City of Hope Cancer Center between 11/1996 and 11/1999 were analyzed. There were 21 males and 13 females, with a median age of 61 years (range: 36-97). Diagnoses included gastric malignancy (n = 28), hemorrhage from diffuse gastritis (n = 4), gastric necrosis with perforation (n = 1), and an aortogastric fistula (n = 1). The operative intent was curative in 22, and palliative in 6 cancer patients. Procedures included total (n = 14), subtotal (n = 9), distal (n = 8), and proximal gastrectomy (n = 3). Reconstruction techniques were Roux-Y (n = 25), BII (n = 5), primary esophagogastric anastomosis (n = 3), and primary gastric closure (n = 1). Twenty patients had prior abdominal operations (59%); 10 underwent resection of additional organs (29%), including 2 splenectomies. The median lymph node count was 24, and 20 cancer patients had a R0 resection (71%). Postoperative complications occurred in 14 patients (41%; major: 26%), with 3 in-hospital deaths and one 90-day fatality (90-day mortality: 12%). Predictors of complications were benign diagnosis (p = 0.01), emergency procedure (p = 0.01), and splenectomy (prior or concurrent) (p = 0.02). Cancer diagnosis (vs. benign) and nonemergent gastrectomy (vs. emergency) were each associated with lower mortality (4 vs. 50%, p = 0.01), median length of stay (12 vs. 19 d, p = 0.02), and tube feed duration (7 vs. 194 d, p = 0.04). Gastrectomies for cancer with curative intent (vs. palliative or therapeutic) had no mortality (p = 0.004), a major complication rate of 14% (p = 0.02), and a median stay of 12 days (p = n.s.). For patients with gastric cancer, pathologic stage was the only multivariate predictor of survival (p = 0.04) at a median follow-up of 9 months (15 for survivors); a median survival for patients with potentially curable disease (stage IA-IIIB) has not yet been reached.
CONCLUSIONS: Gastrectomies for cancer, especially when done electively with curative intent, can lead to excellent postoperative recovery. Palliative gastrectomies or emergency procedures for "benign" conditions have significantly more complicated outcomes.

Entities:  

Mesh:

Year:  2002        PMID: 12397783

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis.

Authors:  Sabrina M Ebinger; René Warschkow; Ignazio Tarantino; Bruno M Schmied; Ulrich Güller; Marc Schiesser
Journal:  Gastric Cancer       Date:  2015-09-21       Impact factor: 7.370

2.  Epidemiology of surgically treated gastric cancer in the United States, 1988-2000.

Authors:  Reid M Wainess; Justin B Dimick; Gilbert R Upchurch; John A Cowan; Michael W Mulholland
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

3.  IL-6 serum levels predict postoperative morbidity in gastric cancer patients.

Authors:  Antoni M Szczepanik; Lucyna Scislo; Thecla Scully; Elzbieta Walewska; Maciej Siedlar; Piotr Kolodziejczyk; Marzena Lenart; Magdalena Rutkowska; Aleksander Galas; Antoni Czupryna; Jan Kulig
Journal:  Gastric Cancer       Date:  2011-04-20       Impact factor: 7.370

4.  Survival outcomes of management in metastatic gastric adenocarcinoma patients.

Authors:  Huang-Ming Hu; Hui-Jen Tsai; Hsiu-Ying Ku; Su-Shun Lo; Yan-Shen Shan; Hung-Chi Chang; Yee Chao; Jen-Shi Chen; Shu-Chen Chen; Chun-Ju Chiang; Anna Fen-Yau Li; Hsiu-Po Wang; Tsang-En Wang; Li-Yuan Bai; Ming-Shiang Wu; Li-Tzong Chen; Tsang-Wu Liu; Yi-Hsin Yang
Journal:  Sci Rep       Date:  2021-11-30       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.